WP744 is a novel anthracycline with enhanced activity against neuroblastoma

Journal of Surgical Research

Volumn 121, Issue 2, 2004, Pages 187-196

  Inge, Thomas H ^a,b,d   Harris, Nathaniel L ^b   Wu, Jianqiang ^b   Azizkhan, Richard G ^a,b   Priebe, Waldemar ^c  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

anthracycline; apoptosis; cell death; chemotherapy; doxorubicin; neuroblastoma; WP631; WP744; WP769

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CASPASE; DAUNORUBICIN DERIVATIVE; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; TETRAZOLIUM; UNCLASSIFIED DRUG; WP 631; WP 744; WP 769;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DNA BINDING; DRUG POTENCY; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME INHIBITION; FLOW CYTOMETRY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; NEUROBLASTOMA CELL; ONCOGENE C MYB; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTHRACYCLINES; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; P-GLYCOPROTEIN;

EID: 6344246111     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jss.2004.03.027     Document Type: Article

References (50)

1. G.M. Brodeur, C. Azar, M. Brother, J. Hiemstra, B. Kaufman, H. Marshall, J. Moley, A. Nakagawara, R. Saylors, N. Scavarda Neuroblastoma. Effect of genetic factors on prognosis and treatment Cancer 70 1992 1685
2. D.M. Green, M.J. Coppes, N.E. Breslow, P.E. Grundy, M.L. Ritchey, J.B. Beckwith, P.R.M. Thomas, G.J. D'Angio Wilms TumorIn P.A. Pizzo D.G. Poplack Principles and Practice of Pediatric Oncology 1997 Lippincott-Raven Philadelphia 733 760
3. K.K. Matthay, J.G. Villablanca, R.C. Seeger, D.O. Stram, R.E. Harris, N.K. Ramsay, P. Swift, H. Shimada, C.T. Black, G.M. Brodeur, R.B. Gerbing, C.P. Reynolds Children's Cancer Group Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid N. Engl. J. Med. 341 1999 1165
4. Anthracycline Antibiotics. Novel Analogues, Methods of Delivery, and Mechanisms of Action. Washington, DC: American Chemical Society, 1995.
5. A. Rebbaa, P.M. Chou, M. Emran, B.L. Mirkin Doxorubicin-induced apoptosis in caspase-8-deficient neuroblastoma cells is mediated through direct action on mitochondria Cancer Chemother. Pharmacol. 48 2001 423
6. S. Fulda, S.A. Susin, G. Kroemer, K.M. Debatin Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells Cancer Res. 58 1998 4453
7. D. Nielsen, C. Maare, T. Skovsgaard Cellular resistance to anthracyclines Gen. Pharmacol. 27 1996 251
8. D.A. Gewirtz A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin Biochem. Pharmacol. 57 1999 727
9. S.E. Bates, L.A. Mickley, Y.N. Chen, N. Richert, J. Rudick, J.L. Biedler, A.T. Fojo Expression of a drug resistance gene in human neuroblastoma cell lines modulation by retinoic acid-induced differentiation Mol. Cell Biol. 9 1989 4337
10. A. Levchenko, B.M. Mehta, B.A. Spengler, A.A. Narkar, R. Fonti, J.L. Biedler, T. Tsuruo, S.M. Larson Measurement of P-glycoprotein expression in multidrug-resistant human neuroblastoma cell lines using self-competitive binding assay Anal. Biochem. 236 1996 338
11. F. Zunino, P. Perego, S. Pilotti, G. Pratesi, R. Supino, F. Arcamone Role of apoptotic response in cellular resistance to cytotoxic agents Pharmacol. Ther. 76 1997 177
12. K. Ueda, M.M. Cornwell, M.M. Gottesman, I. Pastan, I.B. Roninson, V. Ling, J.R. Riordan The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein Biochem. Biophys. Res. Commun. 141 1986 956
13. S.E. Bates, C.Y. Shieh, M. Tsokos Expression of mdr-1/P-glycoprotein in human neuroblastoma Am. J. Pathol. 139 1991 305
14. H.S. Chan, G. Haddad, P.S. Thorner, G. DeBoer, Y.P. Lin, N. Ondrusek, H. Yeger, V. Ling P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma N. Engl. J. Med. 325 1991 1608
15. E. Ferrandis, J. Da Silva, G. Riou, I. Benard Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse Cancer Res. 54 1994 2256
16. L.J. Goldstein, A.T. Fojo, K. Ueda, W. Crist, A. Green, G. Brodeur, I. Pastan, M.M. Gottesman Expression of the multidrug resistance, MDR1, gene in neuroblastomas J. Clin. Oncol. 8 1990 128
17. L. Helson, B. Member, C. Helson Importance of clinical exposure on verapamil enhancement of adriamycin-vincristine cytotoxicity in human neuroblastoma Cancer Drug Deliv. 1 1984 303
18. M.P. LaQuaglia, E.B. Kopp, B.A. Spengler, M.B. Meyers, J.L. Biedler Multidrug resistance in human neuroblastoma cells J. Pediatr. Surg. 26 1991 1107
19. J.L. Teillaud, N. Gruel, J. Moncuit, Z. Mishal, W.H. Fridman, T.J. Lampidis, H. Tapiero Structurally different anthracyclines provoke different effects on cell cycle and tumor B cell differentiation Biomed. Pharmacother. 52 1998 282
20. P. Perego, E. Corna, M. De Cesare, L. Gatti, D. Polizzi, G. Pratesi, R. Supino, F. Zunino Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines Curr Med Chem. 8 2001 31
21. F. Arcamone, F. Animati, M. Bigioni, G. Capranico, C. Caserini, A. Cipollone, M. De Cesare, A. Ettorre, F. Guano, S. Manzini, E. Monteagudo, G. Pratesi, C. Salvatore, R. Supino, F. Zunino Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides Biochem. Pharmacol. 57 1999 1133
22. W. Priebe, N.T. Van, T.G. Burke, R. Perez-Soler Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity Anticancer Drugs 4 1993 37
23. W. Priebe, R. Perez-Soler Design and tumor targeting of anthracyclines able to overcome multidrug resistance a double-advantage approach Pharmacol. Ther. 60 1993 215
24. Y. Zou, Y.H. Ling, N.T. Van, W. Priebe, R. Perez-Soler Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties Cancer Res. 54 1994 1479
25. W. Priebe, R. Perez-Soler Sugar-modified anthracyclines a search for drugs able to overcome multidrug resistance Z.J. Withers K.A. Nieforth 2004 Marcel Dekker, Inc New York
26. B. Martin, A. Vaquero, W. Priebe, J. Portugal Bisanthracycline WP631 inhibits basal and Sp1-activated transcription initiation in vitro Nucleic Acids Res. 27 1999 3402
27. T.H. Inge, L.K. Casson, W. Priebe, J.O. Trent, K.E. Georgeson, D.M. Miller, P.J. Bates Importance of Sp-1 consensus motifs in the MYCN promoter Surgery 132 2002 232
28. N. Keshelava, R.C. Seeger, S. Groshen, C.P. Reynolds Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy Cancer Res. 58 1998 5396
29. N. Keshelava, R.C. Seeger, C.P. Reynolds Drug resistance in human neuroblastoma cell lines correlates with clinical therapy Eur. J. Cancer 33 1997 2002
30. W. Lutz, M. Stohr, J. Schurmann, A. Wenzel, A. Lohr, M. Schwab Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells Oncogene 13 1996 803
31. M.C. Alley, D.A. Scudiero, A. Monks, M.L. Hursey, M.J. Czerwinski, D.L. Fine, B.J. Abbott, J.G. Mayo, R.H. Shoemaker, M.R. Boyd Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay Cancer Res. 48 1988 589
32. I. Nicoletti, G. Migliorati, M.C. Pagliacci, F. Grignani, C. Riccardi A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry J. Immunol. Methods 139 1991 271
33. S. Fulda, W. Lutz, M. Schwab, K.M. Debatin MycN sensitizes neuroblastoma cells for drug-induced apoptosis Oncogene 18 1999 1479
34. S.J. Martin, C.P. Reutelingsperger, A.J. McGahon, J.A. Rader, R.C. van Schie, D.M. LaFace, D.R. Green Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus inhibition by overexpression of Bcl-2 and Abl J. Exp. Med. 182 1995 1545
35. X. Bian, L.M. McAllister-Lucas, F. Shao, K.R. Schumacher, Z. Feng, A.G. Porter, V.P. Castle, A.W. Opipari Jr NF-κB activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells J Biol. Chem. 276 2001 48921
36. S. Faderl, Z. Estrov, H.M. Kantarjian, D. Harris, Q. van, I. Fokt, T. Przewloka, C. Godlewski, J.M. Woynarowski, W. Priebe WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity Anticancer Res. 21 2001 3777
37. M. Haber, S.B. Bordow, P.S. Haber, G.M. Marshall, B.W. Stewart, M.D. Norris The prognostic value of MDR1 gene expression in primary untreated neuroblastoma Eur. J. Cancer 33 1997 2031
38. H.S. Chan, G. Haddad, P.S. Thorner, G. DeBoer, Y.P. Lin, N. Ondrusek, H. Yeger, V. Ling P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma [see comments] N. Engl. J. Med. 325 1991 1608
39. C.R. Dhooge, B,M. De Moerloose, Y.C. Benoit, N. Van Roy, Philippe, G.G. Laureys Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma Cancer 80 1997 1250
40. M. Favrot, V. Combaret, E. Goillot, J.P. Wagner, E. Bouffet, F. Mazingue, A. Thyss, P. Bordigoni, G. Delsol, C. Bailly Expression of P-glycoprotein restricted to normal cells in neuroblastoma biopsies Br. J. Cancer 64 1991 233
41. E.B. Thompson The many roles of c-Myc in apoptosis Annu. Rev. Physiol. 60 1998 575
42. S. Fulda, W. Lutz, M. Schwab, K.M. Debatin MycN sensitizes neuroblastoma cells for drug-triggered apoptosis Med. Pediatr. Oncol. 35 2000 582
43. S. Fulda, H. Sieverts, C. Friesen, I. Herr, K.M. Debatin The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells Cancer Res. 57 1997 3823
44. S. Hopkins-Donaldson, P. Yan, K.B. Bourloud, A. Muhlethaler, J.L. Bodmer, N. Gross Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells Oncogene 21 2002 6132
45. S. Fulda, M. Los, C. Friesen, K.M. Debatin Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system Int. J. Cancer 76 1998 105
46. Anthracycline Antibiotics: New Analogues, Methods of Deliivery, and Mechanisms of Action. Washington, DC: American Chemical Society, 1995.
47. J. Portugal, B. Martin, A. Vaquero, N. Ferrer, S. Villamarin, W. Priebe Analysis of the effects of daunorubicin and WP631 on transcription Curr. Med. Chem. 8 2001 1
48. F. Leng, W. Priebe, J.B. Chaires Ultratight DNA binding of a new bisintercalating anthracycline antibiotic Biochemistry 37 1998 1743
49. A.C. Bharti, B.B. Aggarwal Nuclear factor-kappa B and cancer its role in prevention and therapy Biochem. Pharmacol. 64 2002 883
50. B. Haefner NF-kappa B arresting a major culprit in cancer Drug Discov. Today 7 2002 653